Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6(1):11. https://doi.org/10.1186/1741-7015-6-11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SFT, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906. https://doi.org/10.1016/j.cell.2009.10.027

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80. https://doi.org/10.1126/science.aaa6204

Article  CAS  PubMed  Google Scholar 

Wu D, Liu L, Jiang Y, Qian Z, You Y, Ning X, Zhang F, Wang Y, Zhang Y (2025) Collagen dynamics in the breast cancer tumor microenvironment and therapeutic perspectives. Discov Onc 17(1):9. https://doi.org/10.1007/s12672-025-04182-8

Article  CAS  Google Scholar 

Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Intgr Biol 7(10):1120–1134. https://doi.org/10.1039/c5ib00040h

Article  CAS  Google Scholar 

Hynes RO, Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687. https://doi.org/10.1016/S0092-8674(02)00971-6

Article  PubMed  Google Scholar 

Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119(19):3901. https://doi.org/10.1242/jcs.03098

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22. https://doi.org/10.1038/nrc2748

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14(9):598–610. https://doi.org/10.1038/nrc3792

Article  CAS  PubMed  PubMed Central  Google Scholar 

Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20(3):203–213. https://doi.org/10.1023/A:1022983000355

Article  CAS  PubMed  Google Scholar 

Yao ES, Zhang H, Chen Y-Y, Lee B, Chew K, Moore D, Park C (2007) Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67(2):659–664. https://doi.org/10.1158/0008-5472.CAN-06-2768

Article  CAS  PubMed  Google Scholar 

Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137(1):231–245. https://doi.org/10.1083/jcb.137.1.231

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goodman SL, Picard M (2012) Integrins as therapeutic targets. Trends Pharmacological Sci 33(7):405–412. https://doi.org/10.1016/j.tips.2012.04.002

Article  CAS  Google Scholar 

Alday-Parejo B, Stupp R, Rüegg C (2019) Are integrins still practicable targets for anti-cancer therapy? Cancers 11(7):978. https://doi.org/10.3390/cancers11070978

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madamanchi A, Santoro SA, Zutter MM (2014) In: Gullberg D (ed I Domain Integrins. α2β1 Integrin. Springer, Netherlands, Dordrecht, pp 41–60

Yeh Y-C, Lin H-H, Tang M-J (2012) A tale of two collagen receptors, integrin β1 and discoidin domain receptor 1, in epithelial cell differentiation. Am J Physiol-Cell Physiol 303(12):C1207–C1217. https://doi.org/10.1152/ajpcell.00253.2012

Taddei I, Deugnier M-A, Faraldo MM, Petit V, Bouvard D, Medina D, Fässler R, Thiery JP, Glukhova MA (2008) β1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 10(6):716–722. https://doi.org/10.1038/ncb1734

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lampi MC, Reinhart-King CA (2018) Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials. Sci Transl Med 10(422):eaao0475. https://doi.org/10.1126/scitranslmed.aao0475

Hall CL, Dai J, van Golen KL, Keller ET, Long MW (2006) Type I collagen receptor (α2β1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66(17):8648–8654. https://doi.org/10.1158/0008-5472.CAN-06-1544

Article  CAS  PubMed  Google Scholar 

Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O’rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM (2011) The α 2 β 1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 121(1):226–237. https://doi.org/10.1172/JCI42328

Article  CAS  PubMed  Google Scholar 

Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, Paulweber B, Clar H, Hofmann G, Samonigg H, Krippl P (2006) Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 97(1):67–72. https://doi.org/10.1007/s10549-005-9089-4

Article  CAS  PubMed  Google Scholar 

Moritz MNO, Merkel AR, Feldman EG, Selistre-de-Araujo HS, Rhoades (Sterling) JA (2021) Biphasic α2β1 integrin expression in breast cancer metastasis to bone. IJMS 22(13):6906. https://doi.org/10.3390/ijms22136906

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M-C, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122(3):899–910. https://doi.org/10.1172/JCI45817

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuczek DE, Larsen AMH, Thorseth M-L, Carretta M, Kalvisa A, Siersbæk MS, Simões AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Grøntved L, Madsen DH (2019) Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer 7(1):68. https://doi.org/10.1186/s40425-019-0556-6

Article  PubMed  PubMed Central  Google Scholar 

Hu Q, Zhu Y, Mei J, Liu Y, Zhou G (2025) Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol 18(1):65. https://doi.org/10.1186/s13045-025-01717-y

Article  PubMed  PubMed Central  Google Scholar 

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS et al (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544–548. https://doi.org/10.1038/nature25501

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Hegde S, DeNardo DG (2017) Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. ImmunotherapyCancer Immunol Immunother 66(8):1037–1048. https://doi.org/10.1007/s00262-017-2003-1

Article  CAS  Google Scholar 

Strelnikov VV, Kuznetsova EB, Tanas AS, Rudenko VV, Kalinkin AI, Poddubskaya EV, Kekeeva TV, Chesnokova GG, Trotsenko ID, Larin SS, Kutsev SI, Zaletaev DV, Nemtsova MV, Simonova OA (2021) Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer. Sci Rep 11(1):2264. https://doi.org/10.1038/s41598-021-81851-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jafarpour S, Yazdi M, Nedaeinia R, Vatandoost N, Ferns GA, Salehi R (2023) Sta